On October 16, 2020, the FDA granted full approval for our acute myeloid leukemia (AML) medicine.

Learn more about the recent FDA approval of our neuromyelitis optica spectrum disorder (NMOSD) medicine.

Learn more about the recent FDA approval of our spinal muscular atrophy (SMA) medicine.

On August 15, 2019, the FDA approved Genentech’s personalized medicine for two different indications. 

On June 10, 2019, the FDA granted accelerated approval for a new Genentech medicine in combination with bendamustine plus Rituxan (rituximab) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma who have received at least two prior therapies.

On May 15, 2019, the FDA approved a fixed-duration, chemotherapy-free combination of Genentech medicines for people with previously untreated chronic lymphocytic leukemia.

On May 3, 2019, the FDA approved a Genentech medicine for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant (before surgery) taxane and Herceptin-based treatment.

On March 18, 2019, the FDA approved Genentech’s immunotherapy, in combination with chemotherapy (carboplatin and etoposide), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer.

On March 8, 2019, the FDA granted accelerated approval to a Genentech medicine for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer in people whose tumors express PD-L1, as determined by an FDA-approved test.

Genentech, a member of the Roche Group, today announced the appointment of Alexander Hardy to chief executive officer, effective March 1, 2019.

On December 6, 2018, the FDA granted approval to a new immunotherapy combination for the initial treatment of people with metastatic non-squamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.

On November 21, 2018, the FDA approved a Genentech medicine, in combination with azacitidine, or decitabine, or LDAC, for people newly-diagnosed with AML who are age 75 years or older, or who are ineligible for intensive chemotherapy due to coexisting medical conditions. This indication is approved under accelerated approval based on response rates. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

On October 24, 2018, the FDA approved the first and only single-dose, oral antiviral medicine to treat the flu. 

On October 4, 2018, the FDA approved a Genentech medicine as a new prophylactic (preventative) treatment for adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors, making it the only approved medicine for hemophilia A with and without factor VIII inhibitors that can be self-administered under the skin (subcutaneously) once weekly, every two weeks or every four weeks.

On June 13, 2018 the FDA approved a Genentech medicine for the treatment of women with advanced (stage III or IV) epithelial ovarian, fallopian tube or primary peritoneal cancer following initial surgical resection.

On June 8, 2018, the FDA approved a Genentech medicine for people with previously treated chronic lymphocytic leukemia.

On December 20, 2017, the FDA approved a Genentech medicine for adjuvant (after surgery) treatment of HER2-positive early breast cancer at high risk of recurrence.

On November 16, 2017, the FDA approved a Genentech medicine as a treatment option for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV).

On November 16, the FDA approved a Genentech medicine as a prophylactic (preventative) treatment for adults and children with hemophilia A with factor VIII inhibitors that can be self-administered once weekly by injection under the skin (subcutaneously).

On November 6, 2017, the FDA approved a Genentech medicine for the treatment of people with a specific type of lung cancer.

On June 22, 2017, the FDA approved a Genentech medicine for subcutaneous (under the skin) injection for the treatment of certain blood cancers.

On April 17, 2017, the FDA granted approval to a Genentech medicine for the monthly treatment of all forms of diabetic retinopathy, a potentially blinding eye disease.

On April 17, 2017, the FDA granted accelerated approval to a Genentech cancer immunotherapy medicine as an initial treatment for certain people with advanced bladder cancer.

On December 6, 2016 the FDA approved a medicine for women with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.

On October 18, 2016, the FDA granted approval to a new cancer immunotherapy medicine for the treatment of a type of metastatic lung cancer.

On average, 5-20% of the US population gets the flu each year, and more than 200,000 are hospitalized from seasonal flu related complications. To recognize flu symptoms, remember Flu F.A.C.T.S. (Fever, Aches, Chills, (extreme) Tiredness, and Sudden Onset).

On May 18, 2016, the FDA granted accelerated approval to a new cancer immunotherapy medicine for the treatment of a specific type of advanced bladder cancer.

On April 11, 2016, the FDA granted accelerated approval to a new medicine for the treatment of a hard-to-treat type of chronic lymphocytic leukemia.

On February 26, 2016, the FDA approved a Genentech medicine for people with follicular lymphoma whose disease did not respond to or returned after treatment with another medicine.

On December 11, 2015, the FDA granted accelerated approval to a new medicine for the treatment of a specific type of lung cancer.

On November 10, 2015, the FDA approved a new medicine for the treatment of advanced melanoma.

On February 6, 2015, the FDA approved a Genentech Medicine for the treatment of diabetic retinopathy in people with diabetic macular edema (DME).

On November 14, 2014, a Genentech medicine received FDA approval for the treatment of women with platinum-resistant, recurrent, epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received no more than two prior chemotherapy regimens.

On October 15, 2014, the FDA approved a medicine for the treatment of idiopathic pulmonary fibrosis (IPF).

On August 14, 2014, a Genentech medicine received FDA approval for use in persistent, recurrent or metastatic cervical cancer. It is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone.

On March 21, 2014, the FDA approved a Genentech medicine for people 12 years of age and older for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives.

We're presenting important new findings on unapproved and investigational medicines at ASH 2013. Read press releases and learn about our presence at ASH this year.

On November 1, 2013, the FDA approved a new Genentech medicine for people with previously untreated CLL. It was the first medicine approved with the FDA’s Breakthrough Therapy Designation.

Genentech to report new advances at the American Society of Clinical Oncology Annual MeetingGenentech will present important new data from studies of several cancer medicines at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) from May 31-June 4, 2013, in Chicago.This page is intended to be a media resource for Genentech developments at ASCO. It will be updated frequently throughout the meeting.

On June 8, 2012, a Genentech medicine was approved by the FDA for previously untreated HER2-positive metastatic breast cancer.

Genentech will present important new data on several cancer medicines at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO).

Genentech, the Banner Alzheimer's Institute, and the National Institutes of Health are collaborating on the first-ever prevention trial in cognitively healthy individuals who are likely to develop Alzheimer's disease due to their genetic history.

On August 17, 2011, a Genentech medicine was approved by the FDA for a type of inoperable or metastatic melanoma.